MCRT Webcast EHA 2020: Expert Panel Q&A

Описание: 0:21 I often come across the term “living with myeloma.”  Is this term relevant to the average patient who achieves a stringent complete response following stem cell transplant (ASCT)? Would he/she continue to expect fatigue or continue to note bone degradation during remission? Are chances of infection still more likely than a normal person, or are these effects of active myeloma?
2:04 The results of the COLUMBA trial phase III for relapsed/refractory myeloma patients show that Darzalex Faspro is or the sub q shot is about the same as Darzalex. It has recently been approved by the FDA here in the United States.  What timeline would you anticipate for availability in Europe?
3:58 You talked a little bit, Dr. Nahi, about KRd vs. VRd in newly diagnosed myeloma patients and you’re saying the standard is, basically, VRd, that you’ll be using.  And we have a question submitted: he had been suffering from asymptomatic IGg Kappa myeloma since 2016 and he’s 74, had 70% plasma cells four years ago.  What’s the variable that makes treatment begin?
5:36 Please go over the names of the CAR-T trials, people get confused about different results in different studies, are any of these trials available in the US or are these only European study?
10:26 I wanted to follow up and ask you a little more about that because at the beginning of the program you were talking about this earlier use, of BiTEs as well.  What else would you do at the beginning of treatment?  For example, we start with VRd, stem cell transplants, maintenance treatment, etc.  But if you did a CAR-T upfront, what kind of maintenance would you do for follow up?
15:10 I am presently in KRd maintenance for 1 year following 4 rounds of KRd induction and ASCT clinical trial using elotuzamab with NK cells. And he has 17p del with Lambda light chain myeloma. If we see progression, would you suggest an elotuzumab or daratumamab addition, what do you do from there?
18:08 In high-risk myeloma when should you use a quad therapy?  Is it for everybody?
25:38 Do you change the treatment when a patient goes from MRD-positive to MRD-negative?
32:04 Have there been any maintenance therapy post-stem cell transplant (ASCT)?  Like using monoclonal antibodies or other combinations?
37:31 A heavily treated patient has had heart issues with Kyprolis, had CAR T therapy with 19 months of remission and has the 17p del, diagnosed in 2014.  Are CelMoDs an option?
42:10 Why is CAR T less effective in myeloma compared to lymphoma or leukemia?
48:45 How do you see things progressing in myeloma in the COVID environment?

The Myeloma Crowd brings information from the experts to the patients! Learn more at https://www.myelomacrowd.org/

HealthTree helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at https://www.healthtree.org/